A Phase II, Open Label, Randomized Controlled Pilot Study Evaluating Trimethoprim in Patients Commencing Androgen Deprivation Therapy for Prostate Cancer

The researchers hope to learn if Trimethoprim, 150mg taken daily for 3 months, is a safe and effective way to reduce folate levels at time of Androgen Deprivation Therapy (ADT) in men with advanced prostate cancer.
This study will help find out what effects, good and/or bad, this drug has on people who take it and on its effect on the disease. The safety of this drug in humans has been tested in prior research studies; however, some side effects may not yet be known.

Start Date01 Nov 2024

Sponsor / Collaborator

University of Texas Health Science Center At San Antonio

ChiCTR2200066181 / RecruitingPhase 4IIT

A study on the effect of trimethoprim plus thioglycollate gel filling for the prevention of postoperative stricture in large esophageal ESD

Start Date14 Nov 2022

Sponsor / Collaborator-

NCT05063422 / CompletedPhase 1IIT

Retentive Strength of Various Dental Adhesives on Various Types of Residual Ridged

To compare the retentive strength of different form of commercially available denture adhesives (paste, powder and cushion) on different form of residual ridges.
To evaluate the effect of various denture adhesives on efficiency of complete dentures in patients with different alveolar ridges.

Start Date18 Aug 2022

Sponsor / Collaborator

Altamash Institute of Dental Medicine

100 Clinical Results associated with Trimethoprim

100 Translational Medicine associated with Trimethoprim

100 Patents (Medical) associated with Trimethoprim

15,108

Literatures (Medical) associated with Trimethoprim

01 Jan 2025·FOOD CHEMISTRY

Extraction of phenolic acids and tetramethylpyrazine in Shanxi aged vinegar base on vortex-assisted liquid-liquid microextraction-hydrophobic deep eutectic solvent: COSMO-RS calculations and ANN-GA optimization

Article

Author: Zhang, Ziqing ; Bai, Baoqing ; Bo, Tao ; Zhang, Jinhua ; Meng, Siyuan ; Chen, Rui ; Yang, Yukun ; Fan, Sanhong ; Guo, Yanli

In this study, vortex-assisted liquid-liquid microextraction (VA-LLME) based on hydrophobic deep eutectic solvents (HDES) was used to efficiently and sustainably extract five phenolic acids and tetramethylpyrazine (TMP) from Shanxi aged vinegar (SAV). The VA-LLME technique was employed to investigate the extraction mechanism of HDES with the best extraction performance for the target compounds using a conductor-like screening model for real solvents (COSMO-RS). An artificial neural network combined with a genetic algorithm (ANN-GA) was developed to optimize the extraction conditions based on single-factor and response surface methodology, while also analyzing the interactive effects on the phenolic acids and TMP in the extracted solution during the extraction phase. The optimized conditions were determined, and the greenness of the procedure was evaluated using an analytical greenness metric, indicating that this technique can serve as a green alternative for the determination of phenolic acids and TMP in SAV.

01 Jan 2025·WATER RESEARCH

Combined ozonation-biological activated carbon process for antibiotic resistance control in treated effluent from wastewater treatment plant

Article

Author: Xue, Xi ; Hu, Jiangyong ; Zhang, Xinyang

Biological activated carbon (BAC) treatment plays a crucial role in wastewater treatment plants due to its economic and effective promotion of organic matter degradation or mineralization. However, whether the changes in antibiotic resistance (AR) resulting from BAC or O₃-BAC treatment are related to environmental factors remains unclear, as previous studies have primarily focused on isolated aspects, or have combined these aspects without systematically comparing the BAC and O₃-BAC treatment processes or analyzing their interrelationships. In this study, to gain a clearer understanding of the factors related to AR during the BAC treatment, the treatment process of BAC and O₃-BAC were comprehensively compared, including antibiotics removal, wastewater matrix changes, antibiotic resistant bacteria (ARB), antibiotic resistance genes (ARGs), and bacterial community characteristics. The roles of O₃ pretreatment and the bed depth of BAC were also clarified. ARGs were found to be not as sensitive to ozone as ARB. In addition, further strengthening of control measures should be needed for trimethoprim and tetracycline, due to their low removal efficiencies by ozone pretreatment, and their close relationship with the increased AR. Besides, 2 mg/L ozonation pretreatment could significantly influence the microbial community composition of wastewater and biofilm samples, while 1 mg/L ozonation could not. Finally, the correlation of environmental factors, bacterial communities, and ARGs revealed that to reduce the AR risks of O₃-BAC treatment, antibiotics in wastewater should be strictly controlled, since they were positively correlated with the accumulation of ARGs and Pseudomonadota, Actinomycetota, and Bacteroidota, which were responsible for carrying and disseminating ARGs. The results showed that higher dose ozonation pre-treatment and longer bed depth of BAC process could help control the AR of BAC.

01 Jan 2025·JOURNAL OF PEDIATRICS

Prenatal and Postnatal Exposure to Antibiotics and the Risk of Type 1 Diabetes in Finnish Children: A Registry-based Study

Article

Author: Gissler, Mika ; Lundqvist, Annamari ; Metsälä, Johanna ; Virtanen, Suvi M. ; Virtanen, Suvi M ; Hakola, Leena ; Virta, Lauri J. ; Virta, Lauri J

OBJECTIVE:

To study whether prenatal and postnatal exposure to antibiotics is associated with the risk of type 1 diabetes in childhood.

STUDY DESIGN:

This case cohort study included 2869 children diagnosed with type 1 diabetes by the end of 2009 who were born between January 1, 1996, and December 31, 2008, in Finland and a reference cohort (n = 74 263) representing 10% of each birth cohort. Exposure to antibiotics was assessed in different time periods. The data were derived from Special Reimbursement Register, Drug Prescription Register, and Population Register and analyzed with weighted Cox proportional hazards regression models.

RESULTS:

Exposure to any antibiotics before or during pregnancy, in the neonatal ward, during the first year of life, or during the 2 first years of life, was not associated with the risk of type 1 diabetes in the offspring. Exposure to macrolides in the year preceding pregnancy (adjusted hazard ratio [HR], 1.17; 95% CI, 1.02-1.33) and to sulfonamides and trimethoprim during pregnancy (adjusted HR, 1.91; 95% CI, 1.07-3.41) was associated with an increased risk of type 1 diabetes in the offspring. Exposure to sulfonamides and trimethoprim during first 2 years of life was associated with a decreased risk of type 1 diabetes (adjusted HR, 0.84; 95% CI, 0.73-0.97). The number of antibiotic purchases among mothers or children was not associated with type 1 diabetes risk.

CONCLUSIONS:

Prenatal and postnatal exposure to antibiotics in general did not increase the risk of type 1 diabetes in the offspring. However, the type of antibiotic and timing of exposure may play a role in type 1 diabetes risk.

News (Medical) associated with Trimethoprim

13 Aug 2024

·www.globenewswire.com

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported its financial and operating results for the three months ended June 30, 2024 and provided a business update. “Artelo is entering an unprecedented phase of productivity in clinical development,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Specifically, we look forward to multiple clinical readouts over the next 18 months across our portfolio. Most recently, we received clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for ART26.12 for the treatment of chemotherapy-induced peripheral neuropathy and Phase 1 trial results are expected during the first half of 2025. In addition, we anticipate full enrollment in the Phase 2a portion of the CAReS trial with our lead clinical asset, ART27.13, for the treatment of cancer-related anorexia near the end of 2024 or early 2025. To date, there have been no serious adverse events reported related to the study drug in CAReS. Finally, ART12.11, our proprietary cocrystal of CBD and TMP intended for the treatment of anxiety and depression, is in the final stages of product formulation as an oral solid, creating the potential to enter a clinical study early next year.” “With over $5.6 million of cash and cash equivalents as of June 30, 2024, and the receipt of approximately $1.3 million in cash from the UK government from R&D tax credits on July 10, 2024, we have the momentum to meaningfully advance our asset portfolio over the coming months,” concluded Mr. Gorgas. Other Company Highlights: Presented data from multiple preclinical studies at the 34th Annual International Cannabinoid Research Society Symposium Efficacy of ART26.12 in Breast Cancer-Induced Bone PainResults supporting broad potential utility of FABP Inhibitor platformMultiple studies confirming ART12.11’s potential advantages as a product candidate for the treatment of anxiety related disorders Presented highly encouraging data towards developing a solid dosage form of ART12.11, including comparative data to the Epidiolex formulation of CBD. Epidiolex had annual sales in excess of $700 million in 2023Announced publication of peer-reviewed article highlighting FABP7 as a promising novel target in cancer therapy Financial Results for Quarter Ended June 30, 2024 Cash and Investments: Cash and investments totaled $5.6 million as of June 30, 2024.R&D Expenses: Research and development expenses were $1.7 million for the three months ended June 30, 2024, compared to $0.8 million for the same period in 2023.G&A Expenses: General and administrative expenses were $0.8 million for the three months ended June 30, 2024, compared to $1.0 million for the same period in 2023.Net Loss: For the three months ended June 30, 2024, net loss was $2.4 million, or $0.75 per basic and diluted common share, which included $0.1 million of non-cash expenses, compared to a net loss of $1.6 million, or $0.56 per basic and diluted common share for the three months ended June 30, 2023, which included $0.2 million of non-cash expenses.R&D Tax Credit: Subsequent to the end of the quarter, the Company received approximately $1.3 million in cash on July 10, 2024, from the UK government related to qualified prior research and development expenses. About ART27.13ART27.13 is a G-Protein Coupled Receptor (GPCR) agonist, a highly potent, peripherally restricted new chemical entity, targeting CB1 and CB2 receptors, with the potential to improve body weight, appetite, muscle degeneration, and quality of life in cancer patients. Originally developed by AstraZeneca plc, ART27.13 has been in clinical studies with over 250 subjects. A statistically significant and dose-dependent increase in body weight was observed in patients with back pain who were otherwise healthy. Importantly, the drug enables systemic metabolic effects while minimizing central nervous system-mediated toxicity. Having completed a Phase 1 study in cancer patients where ART27.13 demonstrated an excellent safety profile, Artelo is now advancing it in the CAReS trial as a supportive care therapy for cancer patients suffering from anorexia and weight loss. Currently, there is no FDA-approved treatment for cancer anorexia cachexia syndrome. About CAReSThe Cancer Appetite Recovery Study (CAReS) is a Phase 1b/2a randomized, placebo-controlled trial of the Company’s lead clinical program, ART27.13, in patients with cancer anorexia and weight loss. Cancer-related anorexia, or the lack or loss of appetite in the person with cancer, may result from the cancer and/or its treatment with radiation or chemotherapy. It is common for people with cancer to lose weight. Anorexia and the resulting weight loss can affect a patient’s health, often weakening their immune system and causing discomfort and dehydration. A weight loss of more than 5% can predict a poor outcome for cancer patients and a lower response to chemotherapy. Now completed, the Phase 1b portion of the CAReS study was designed to determine the most effective and safest dose of ART27.13 for dosing in the Phase 2a stage. Currently enrolling, the Phase 2a portion of the CAReS study is designed to determine estimates of activity of ART27.13 in terms of lean body mass, weight gain, and improvement of anorexia. (ISRCTN registry: https://www.isrctn.com/ISRCTN15607817) About ART26.12Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. ART26.12, Artelo’s lead FABP inhibitor cleared by FDA to initiate first-in-human studies, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with an initial clinical study planned for chemotherapy-induced peripheral neuropathy (CIPN). Beyond ART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs have shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, dermatologic conditions, and anxiety disorders. About ART12.11ART12.11 is Artelo’s wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Superior pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@crescendo-ir.com

Phase 1Phase 2Financial StatementClinical Result

12 Aug 2024

·www.globenewswire.com

Locus Biosciences Announces Positive Results from Part 1 of ELIMINATE Phase 2 Trial of the Engineered Bacteriophage Therapy LBP-EC01 Published in The Lancet Infectious Diseases

Primary and secondary objectives were met in the open-label randomized Part 1 of the clinical trial to treat uncomplicated UTIs caused by antibiotic-resistant E. coli Dosing has begun in Part 2, the controlled, double-blind portion of the trial triggered by the success in Part 1 Data support potential of Locus’ engineered bacteriophage platform in combatting the global health crisis of infections caused by multidrug-resistant (MDR) pathogens RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced positive results from Part 1 of its two-part Phase 2 ELIMINATE trial. This Phase 2 trial is evaluating LBP-EC01, a CRISPR-Cas3 genetically engineered bacteriophage therapy designed to treat patients with uncomplicated urinary tract infections (uUTIs) caused by antimicrobial-resistant (AMR) and multi-drug-resistant (MDR) Escherichia coli (E. coli). Data from the randomized, uncontrolled, open-label Part 1 portion of the trial were published in The Lancet Infectious Diseases. Locus also announced that dosing has begun in the randomized, controlled, and blinded Part 2 portion of this Phase 2 study. This clinical trial is supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. Worldwide, an estimated 150 million people are affected by UTIs each year. Approximately 80% of these are caused by E. coli, often including difficult-to-treat strains that are resistant to commonly used antibiotics. Up to 40% of UTI patients experience a recurrence, often within months of the first episode. Both the U.S. Centers for Disease Control and Prevention and the World Health Organization have identified antibiotic-resistant E. coli as an urgent and serious public health threat requiring the development of new treatments. Part 1 of ELIMINATE enrolled 39 adult female patients, across six United States-based clinical centers and had an overall objective of defining a dosing regimen of LBP-EC01 and oral trimethoprim/sulfamethoxazole (TMP/SMX) to advance to Part 2 of the trial. This overall objective was supported by analysis of the primary outcome of pharmacokinetics (PK) in urine and blood, and the secondary outcome of safety, which were assessed on randomized patients dosed at least once with LBP-EC01. In addition, an exploratory outcome of pharmacodynamic (PD) assessments was performed on 16 evaluable patients. “The need for new targeted antibacterial therapies is urgent given the increasing impact of antibiotic-resistant pathogens, which we see in our clinic every day,” said Juvenal E. Martinez, M.D., an investigator in the trial. “As the first Phase 2 engineered bacteriophage trial, ELIMINATE is breaking new ground in the quest to address increasingly prevalent serious MDR infections. This encouraging initial data support the possible utility of bacteriophages and the potential of LBP-EC01 as a therapeutic option to address drug-resistant bacterial infections, such as UTIs, which have a high recurrence rate due to MDR pathogens.” ELIMINATE Trial Part 1 Results The primary and secondary outcomes of Part 1 were met, and a dosing regimen was identified that was well-tolerated and which led to high drug exposure at the site of infection. No serious adverse events were observed in Part 1, and exposure to LBP-EC01 did not lead to any observations of genetic resistance in any subsequently recovered E. coli samples. Part 1 was initiated with three treatment groups focused on intravenous (IV) delivery of a high 1×1011 plaque forming units (PFU)/dose of LBP-EC01 which was halted after three patients discontinued dosing due to non-serious adverse events of mild tachycardia and afebrile chills. Three updated treatment groups, which focused on a short, 3-day course of intra-urethral (i.e., IU or direct to bladder) and lower exposure IV dosing, replaced the original treatment groups. With this updated dosing approach, a rapid reduction of E. coli in urine was observed four hours after the first treatment which was maintained to the day 10 test of cure (TOC) evaluation. All (16 of 16) patients in the evaluable population had complete resolution of UTI symptoms and 14 of 16 (87.5%) patients demonstrated microbiologic cure or reduction of their bacterial infection below 1×103 colony forming units (CFU)/mL in urine by the day 10 TOC. A dosing regimen of LBP-EC01 given for 2 days IU (2×1012 PFU/dose) and given concurrently for 3 days IV (1×1010 PFU/dose) with concomitant oral TMP/SMX (160 mg TMP/800 mg SMX twice daily) has been advanced into Part 2. ELIMINATE Trial Part 2 underway Part 2 of the ELIMINATE trial has been initiated with patient dosing underway. This randomized, controlled, double-blind portion of the trial will evaluate the efficacy, safety, tolerability, and pharmacokinetics of LBP-EC01 with TMP/SMX. Up to 288 female uncomplicated UTI patients will be enrolled and randomized in a 1:1 ratio where patients will receive LBP-EC01 or placebo for the 3-day dosing regimen selected from Part 1. The primary objective will be to evaluate the effect of LBP-EC01 given with TMP/SMX on its ability to treat acute UTIs in patients with a history of UTI recurrence. The impact of the treatment on reducing UTI recurrence and/or extending the duration of time to the next UTI recurrence will be examined as an exploratory endpoint in a 6-month follow-up evaluation. This trial is registered with ClinicalTrials.gov, NCT05488340, and is ongoing. “These milestones represent a huge step forward in the critical fight against MDR. Over the past eight years, we have invested significant resources to build the Locus engineered bacteriophage platform. We developed our high-throughput robotics and AI technology to optimize a fixed set of precisely engineered phages that target over 95 percent of current uropathogenic E. coli strains, including MDR strains. We also built a world-class viral vector manufacturing facility that produces GMP materials at potency and purity levels higher than any others we have seen in the field to date. These Part 1 data validate our platform and support the advancement of a potential first-in-class therapy,” said Paul Garofolo, Co-founder and CEO of Locus. “We are grateful for the participating sites, clinicians, and patients, and our funding partner BARDA. We are eager to build on this positive momentum as we continue Part 2 of the ELIMINATE trial.” For more information on Part 1 of the ELIMINATE trial, visit clinicaltrials.gov using the identifier NCT05488340. Patients interested in participating in Part 2 can visit www.eliminateuti.com. About LBP-EC01LBP-EC01 is a CRISPR-enhanced bacteriophage therapy in development for the treatment of urinary tract infections and other infections caused by the pathogen E. coli. It is a bacteriophage cocktail engineered with a CRISPR-Cas3 construct targeting the E. coli genome. The precision medicine product works through a unique dual mechanism of action utilizing both the natural lytic activity of the bacteriophage along with the DNA-targeting activity of CRISPR-Cas3. LBP-EC01 previously met all primary and secondary endpoints and demonstrated safety and tolerability in a Phase 1b trial. LBP-EC01 is currently being evaluated in a Phase 2 trial for the treatment of UTIs caused by E. coli. In 2020, Locus and BARDA, part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), announced an agreement to co-fund development of LBP-EC01. Under the partnership agreement, contract number 75A50120C00169, BARDA will provide up to $93 million to Locus as part of a $152 million program to support Phase 2 and Phase 3 clinical trials and other activities required to seek marketing approval from the U.S. Food and Drug Administration (FDA) for LBP-EC01. About Locus BiosciencesLocus Biosciences is creating a new class of precision biotherapeutics with clinical-stage engineered bacteriophage treatments for a diverse set of bacterial and microbiome/inflammatory diseases. A world-leading bacteriophage discovery, synthetic biology, and manufacturing platform powers the company. Locus engineers bacteriophage - naturally occurring viruses that target bacteria - to kill pathogenic bacteria, while sparing good bacteria, through programmable precision anti-bacterials with CRISPR-Cas3 and other therapeutic payloads. Its artificial intelligence and machine-learning based discovery engine targets bacteria that are associated with disease across multiple therapeutic areas including infectious disease, immunology, and oncology. Locus has secured multiple non-dilutive partnerships to support development of the company’s platform and programs. These include anti-bacterial partnerships with Biomedical Advanced Research and Development Authority (BARDA) for its lead asset targeting E. coli and Combatting Antibiotic Resistant Bacteria Accelerator (CARB-X) for its asset targeting K. pneumoniae. For more on the Research Triangle Park, N.C.-based company, visit www.locus-bio.com. Media Contact:Gina Mangiaracina6 Degrees gmangiaracina@6degreespr.com

Clinical ResultPhase 2License out/inPhase 1

08 Jul 2024

·www.prnewswire.com

When Our Genes Make Us Sick From Medication

New research is uncovering genetic predispositions to developing DRESS Syndrome RICHMOND, Va., July 8, 2024 /PRNewswire/ -- In honor of National DRESS Syndrome Day, July 16, the DRESS Syndrome Foundation is raising awareness about genetic predispositions to developing severe cutaneous adverse drug reactions (SCARs) like DRESS Syndrome. DRESS is a life-threatening condition that results from taking medications, most commonly antibiotics and anticonvulsants. Researchers are working to reveal the link between our genes and these drugs. The goal is to more effectively treat — and prevent — DRESS Syndrome. Continue Reading National DRESS Syndrome Day 2024 Tasha Tolliver, Executive Director DRESS Syndrome Foundation Dr. Elizabeth Phillips, Vanderbilt University Medical Center "Worldwide, patients are often prescribed medications without a full understanding as to whether these drugs are safe for them to take," explains Tasha Tolliver, Executive Director of the DRESS Syndrome Foundation. "We're thankful that a global team of dedicated researchers is identifying genetic markers that make people susceptible to developing severe drug reactions. This will be a huge step forward in preventing DRESS Syndrome while helping to manage risk and prevent harm." To date, the medical community has discovered that select drugs carry genetic risk factors for getting DRESS Syndrome and other SCARs. The prevalence of individual genes can vary, depending on the population, like Asian, European, Thai, etc. When patients carry a genetic risk, they have a greater chance of developing DRESS or another SCAR from that specific medication. Dr. Elizabeth Phillips is a globally renowned severe drug reaction researcher at Vanderbilt University Medical Center. She and her team are uncovering genetic markers that can predict a patient's likelihood for developing SCARs. They recently discovered that the gene HLA-A*32:01 can increase a person's chance for developing DRESS from the commonly prescribed antibiotic Vancomycin. Dr. Phillips and her team have also developed genetic tests for Vancomycin. Although relatively cheap and easy to do, the tests are not yet widely implemented. With more widespread use, medical providers could prevent and better diagnose DRESS Syndrome cases. Before prescribing a medication like Vancomycin, they could weigh the benefit of receiving it against someone's drug reaction risk. "We are entering an era where these decision support tools can be a tremendous help," says Dr. Phillips. "However, clinical practice is still behind in implementing these tests effectively in pharmacogenomics education. In this rapidly changing field, it is crucial to help doctors, nurses, and pharmacists understand and make decisions." Dr. Phillips suggests that to better prevent and manage SCARs, general medical board certification and CME requirements should also require pharmacogenetics knowledge. National DRESS Syndrome Day takes place each year on July 16. The 2024 theme is "Voices for DRESS." Among other actions, they will recognize medical professionals as "DRESS Heroes" and invite patients and medical experts to share their personal DRESS experiences. What Is DRESS Syndrome ? DRESS stands for Drug Reaction with Eosinophilia and Systemic Symptoms A severe, cutaneous adverse reaction to medication. Symptoms are delayed (2 – 8 weeks) and can occur from taking one of over 50 prescription drugs like antibiotics and anticonvulsants. Five prescription drugs account for over 50% of cases and 56% of reported deaths: Allopurinol, Carbamazepine, Lamotrigine, Sulfamethoxazole/Trimethoprim (Bactrim) and Vancomycin. One in every 1,000 to 10,000 drug exposures will result in DRESS. 10% of people with DRESS will die. DRESS usually begins with rash, fever, lymphadenopathy, and facial swelling; and leads to blood abnormalities and organ injury, typically of the liver, kidneys, lungs, and heart. It can result in long-term autoimmune complications. About The DRESS Syndrome Foundation The DRESS Syndrome Foundation is a 501(c)(3) nonprofit based in Richmond, Virginia. We are a collaborative network of patients, families, researchers, and physicians dedicated to educating about severe adverse drug reactions, while advocating for the advancement of research, treatments, and prevention. We serve patients and their loved ones worldwide. Learn more at: DRESSsyndromefoundation.org Contact: Deanna Lorianni Communications Director DRESS Syndrome Foundation 804.307.6703 [email protected] SOURCE DRESS Syndrome Foundation

100 Deals associated with Trimethoprim

External Link

KEGG	Wiki	ATC	Drug Bank
D00145	Trimethoprim	J01EA01	DB00440

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Urinary Tract Infections	AU	Arrotex Pharmaceuticals Pty Ltd.Startup	02 Aug 1991
Bacterial Infections	US	Monarch Pharmaceuticals LLC	30 May 1980

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03077711 (CTgov)	Phase 4	Urinary Tract Infections	92	Methenamine hippurate (Patients With Recurrent UTIs Arm 1)	zatoiwitke(noclvzacgp) = htqgxcoigt kceslcktsc (awovzactck, jhqfnluogf - rjtboqchyd) View more	-	14 Jan 2020
NCT03077711 (CTgov)	Phase 4	Urinary Tract Infections	92	Trimethoprim (Patients With Recurrent UTIs Arm 2)	zatoiwitke(noclvzacgp) = oaedyevlig kceslcktsc (awovzactck, wmjiehjuhi - ghswxicgsr) View more	-	14 Jan 2020
SP285 (ERA2019)	Not Applicable	Chronic Kidney Diseases creatinine	20	Trimethoprim	onsbegwrtz(irknojzkkw) = jagidzahok bqukdpddxp (wamlzogaxv )	Positive	13 Jun 2019
ASN2014	Not Applicable	Hyponatremia	48	High dose TMP-SMX	upjijtdrvx(pugfzcsqgb) = tqbcldlloq xbtksevnxs (gzgklicksk )	Positive	11 Nov 2014
Pubmed \| Br J Clin Pharmacol	Not Applicable	-	-	Metformin 500 mg	dliexrpinh(pyqvwhuqqm) = rikhhrdmru yuhmxamfgk (jtvtohawgn ) View more	-	01 Nov 2013
Pubmed \| Br J Clin Pharmacol	Not Applicable	-	-	Trimethoprim 200 mg	uuvaqztadl(analbbjkye) = smnayzhudt dijmtprjuo (ntkjbkydvk ) View more	-	01 Nov 2013
AAAAI2013	Not Applicable	Systemic Lupus Erythematosus anti-Ro/SS-A antibody	31	TMP/SMX	vfsnondndf(izorubyfyl) = tnvrazlhdx yxbsyeqfcf (fkcucbhdiv )	Positive	01 Feb 2013
NCT00014911 (CTgov)	Phase 2	Diabetes Mellitus, Type 1	36	Islet Transplantation+Ganciclovir+Sulfamethoxazole+Tacrolimus+Sirolimus+Daclizumab+Pentamidine+Trimethoprim	pfrquakcha(fnjwiwwmuj) = igiimudftq oxkvfftdgx (ytslnzwmoe, ozwhurfywe - ejcxsqeozp) View more	-	17 Oct 2012
AAAAI2007	Not Applicable	Acquired Immunodeficiency Syndrome	6	Sulfa	nqeifyadeq(vueyfznzft) = 5/6 developed cutaneous burning sensation followed by generalized maculopapular rash with a median onset after the last dose of 12 hours. Only antihistamines were used. The symptoms resolved within 6 days (median of 2 days, range 1-6 days) vhanrfljth (elanevnswa )	-	01 Jan 2007

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis